Isocarboxazid API is a pharmaceutical-grade Monoamine Oxidase Inhibitor (MAOI) indicated for the treatment of major depressive disorder, particularly in patients who do not respond adequately to other antidepressant therapies. It acts by irreversibly inhibiting monoamine oxidase (MAO-A and MAO-B) enzymes, increasing the levels of neurotransmitters such as serotonin, norepinephrine, and dopamine in the central nervous system.
By enhancing neurotransmitter availability, Isocarboxazid helps improve mood, emotional stability, and symptoms associated with depressive disorders. It is commonly formulated into oral tablet formulations for psychiatric treatment.
Manufactured under WHO-GMP-certified facilities, our Isocarboxazid API is produced using advanced pharmaceutical manufacturing technologies to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Isocarboxazid API is used in oral pharmaceutical formulations for the treatment of major depressive disorder, particularly in patients with treatment-resistant depression.
Isocarboxazid irreversibly inhibits monoamine oxidase (MAO-A and MAO-B), increasing serotonin, norepinephrine, and dopamine levels in the brain to improve mood and reduce depressive symptoms.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Isocarboxazid API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp